BCM
MRTX

BluePath Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

BluePath Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-894
Closed -$38.9K – 341
2023
Q3 		$38.9K Buy
+894
New +$31.9K 0.04% 203

Other funds holding MRTX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
SS
Simplicity Solutions Minneapolis, Minnesota $3.66B AUM 23.51% 1-Year Est. Return
B
Braslyn New Providence, Bahamas $7.81M AUM 338.68% 1-Year Est. Return

BluePath Capital Management's MRTX Position: Q4 2023 in Review

BluePath Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2023, closing a stake of 894 shares — an estimated $38.9K sold.

BluePath Capital Management first reported a position in MRTX in Q3 2023 and held it in 1 quarter. The position peaked at $38.9K in Q3 2023. 217 funds tracked by Wall St. Rank hold MRTX as of Q4 2023.

  • BluePath Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • BluePath Capital Management sold 894 Mirati Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $38.9K.
  • BluePath Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2023 and held it in 1 quarter.
  • BluePath Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $38.9K in Q3 2023.
  • 217 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2023.

Based on BluePath Capital Management's 13F filing for Q4 2023, filed 11 Jan 2024.